Use of Transgenic Animals as Xenotransplant Donors

  • J. L. Platt
  • J. S. Logan

Abstract

One factor which has contributed to a recent surge in interest in xenotransplantation is the development of transgenic animals for use as xenotransplant donors. The development of these animals not only reflects a certain measure of technical advance, it also results from a rapid expansion of basic knowledge about the molecular hurdles to the xenotransplantation of organs from lower mammals into humans [1]. This chapter will review some of the ways in which genetic engineering can address the immunologic hurdles to xenotransplantation and in doing so further extend basic knowledge.

Keywords

Permeability Hydrolysis Hydrate Carbohydrate Recombination 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Platt, J.L. Hyperacute Xenograft Rejection. R.G. Landes Company, Austin, 1995Google Scholar
  2. 2.
    Good, A.H., Cooper, D.K.C., Malcolm, A.J., et al. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant. Proc. 24, 559, 1992PubMedGoogle Scholar
  3. 3.
    Sandrin, M.S., Vaughan, H.A., Dabkowski, P.L., McKenzie, I.F.C. Antipig IgM antibodies in human serum react predominantly with Galα(1,3)Gal epitopes. Proc.Natl.Acad. Sci.USA 90, 11391, 1993PubMedCrossRefGoogle Scholar
  4. 4.
    Collins, B.H., Parker, W.R., Platt, J.L. Characterization of porcine endothelial cell determinants recognized by human natural antibodies. Xenotransplantation 1, 36, 1994CrossRefGoogle Scholar
  5. 5.
    Galili, U., Swanson, K. Gene sequences suggest inactivation of α-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc.Natl.Acad.Sci.USA 88, 7401, 1991PubMedCrossRefGoogle Scholar
  6. 6.
    Cooper, DKC, Good, AH., Koren, E., et al. Identification of α-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discorant xenografting in man. Transplant. Immunol. 1, 198, 1993CrossRefGoogle Scholar
  7. 7.
    Sandrin, M.S., Fodor, W.L., Mouhtouris, E., et al. Enzymatic remodelling of the carbohydrate surface of a xenogeneic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nature Med. 1, 1261, 1995PubMedCrossRefGoogle Scholar
  8. 8.
    Sharma, A., Okabe, J.F., Birch, P., Platt, J.L., Logan, J.S. Expression of α1,2 fucosyltrans- ferases in transgenic animals to reduce the number of Gal α1,3Gal epitopes. Proc. Natl.Acad.Sci.USA 93, 7190, 1996PubMedCrossRefGoogle Scholar
  9. 9.
    Muir, R. On the relationships between the complements and immune-bodies of different animals. J.Path.Bact. 16, 523, 1911CrossRefGoogle Scholar
  10. 10.
    Miyagawa, S., Hirose, H., Shirakura, R., et al. The mechanism of discordant xenograft rejection. Transplantation 46, 825, 1988PubMedCrossRefGoogle Scholar
  11. 11.
    Dalmasso, A.P., Vercellotti, G.M., Platt, J.L., Bach, F.H. Inhibition of complement- mediated endothelial cell cytotoxicity by decay accelerating factor: Potential for prevention of xenograft hyperacute rejection. Transplantation 52, 530, 1991PubMedCrossRefGoogle Scholar
  12. 12.
    Piatt, J.L., Vercellotti, G.M., Dalmasso, A.P., et al. Transplantation of discordant xenografts: a review of progress. Immunol.Today 11, 450, 1990CrossRefGoogle Scholar
  13. 13.
    Platt, J.L., Bach, F.H. The barrier to xenotransplantation. Transplantation 52, 937, 1991PubMedCrossRefGoogle Scholar
  14. 14.
    Nicholson-Weller, A., March, J.P., Rosenfeld, S.I., Austen, F Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc.Natl.Acad.Sci.USA 80, 5066, 1983PubMedCrossRefGoogle Scholar
  15. 15.
    Pangburn, M.K., Schreiber, R.D., Muller-Eberhard, H.J. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc.Natl.Acad.Sci.USA 80, 5430, 1983PubMedCrossRefGoogle Scholar
  16. 16.
    Matsuo, S., Ichida, S., Takizawa, H., et al. In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J.Exp.Med. 180, 1619, 1994PubMedCrossRefGoogle Scholar
  17. 17.
    Medof, M.E., Kinoshita, T., Nussenzweig, V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J.Exp.Med. 160, 1558, 1984PubMedCrossRefGoogle Scholar
  18. 18.
    White, D.J.G., Oglesby, T., Liszewski, M.K., et al. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Transpl.Proc. 24, 474, 1992Google Scholar
  19. 19.
    Walsh, L.A., Tone, M., Waldmann, H. Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement. Eur.J.Immunol. 21, 847, 1991PubMedCrossRefGoogle Scholar
  20. 20.
    Akami, T., Sawada, R., Minato, N., et al. Cytoprotective effect of CD59 antigen on xenotransplantation immunity. Transplant Proc 24, 485, 1992PubMedGoogle Scholar
  21. 21.
    Kennedy, S.P., Rollins, S.A., Burton, W.V., et al. Protection of porcine aortic endothelial cells from complement-mediated cell lysis and activation by recombinant human CD59. Transplantation 57, 1494, 1994PubMedGoogle Scholar
  22. 22.
    Atkinson, J.P., Oglesby, T.J., White, D., Adams, E.A., Liszewski, M.K. Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor. Clin.Exp.Immunol. 86 (Supp. 1), 27, 1991PubMedGoogle Scholar
  23. 23.
    Oglesby, T.J., Allen, C.J., Liszewski, M.K., White, D.J.G., Atkinson, J.P. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J.Exp.Med. 175, 1547, 1992PubMedCrossRefGoogle Scholar
  24. 24.
    Cary, N., Moody, J., Yannoutsos, N., Wallwork, J., White, D. Tissue expression of human decay accelerating factor, a regulator of complemenent activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection. Transplant. Proc. 25, 400, 1993PubMedGoogle Scholar
  25. 25.
    Kooyman, D.L., Byrne, G.W., McClellan, S., et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 269, 89, 1995PubMedCrossRefGoogle Scholar
  26. 26.
    Diamond, L.E., McCurry, K.R., Platt, J.L., et al. A human CD59 expressed in transgenic mousehearts inhibits activation of complement biologically functional complement regulatory protein in transgenic mice. Transplant Immunol 3, 305, 1995CrossRefGoogle Scholar
  27. 27.
    Byrne, G.W., McCurry, K.R., Kagan, D., et al. Protection of xenogenic endothelium from human complement by expression of CD59 or DAF in transgenic mice. Transplantation 60, 1149, 1995PubMedCrossRefGoogle Scholar
  28. 28.
    Logan, J.S., Martin, M.J. Transgenic swine as a recombinant production system for human hemoglobin. Methods Enzymol. 231, 435, 1994PubMedCrossRefGoogle Scholar
  29. 29.
    Kooyman, D., Byrne, G.W., McClellan, S., et al. Erythroid-specific expression of human CD59 and transfer to vascular endothelial cells. Transplant. Proc. 26, 1241, 1994PubMedGoogle Scholar
  30. 30.
    Kagan, D.T., Platt, J.L., Logan, J.S., Byrne, G.W. Expression of complement regulatory factors using heterologous promoters in transgenic mice. Transplant. Proc. 26, 1242, 1994PubMedGoogle Scholar
  31. 31.
    McCurry, K.R., Kooyman, D.L., Diamond, L., et al. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. Transplantation 59, 1177, 1995PubMedGoogle Scholar
  32. 32.
    Diamond, L.E., Oldham, E.R., Platt, J.L., et al. Cell and tissue specific expression of a human CD59 minigene in transgenic mice. Transplant. Proc. 26, 1239, 1994PubMedGoogle Scholar
  33. 33.
    Diamond, L.E., McCurry, K.R., Oldham, E.R., et al. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 61, 1241, 1996PubMedCrossRefGoogle Scholar
  34. 34.
    Rosengard, A.M., Cary, N.R.B., Langford, G.A., et al. Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. Transplantation 59, 1325, 1995PubMedGoogle Scholar
  35. 35.
    Fodor, W.L., Williams, B.L., Matis, L.A., et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc.Natl.Acad.Sci.USA 91, 11153, 1994PubMedCrossRefGoogle Scholar
  36. 36.
    McCurry, K.R., Kooyman, D.L., Alvarado, CG., et al. Human complement regulatory proteins protect swine-to-primate cadriac xenografts from humoral injury. Nature Med. 1, 423, 1995PubMedCrossRefGoogle Scholar
  37. 37.
    Shin, M.L., Carney, D.F. Cytotoxic action and other metabolic consequences of terminal complement proteins. Prog.in Allergy 40, 44, 1988Google Scholar
  38. 38.
    Morgan, B.P. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem.J. 264, 1, 1989PubMedGoogle Scholar
  39. 39.
    Byrne, G.W., McCurry, K.R., Martin, M.J., et al. Expression of human CD59 and DAF in transgenic pigs: intrinsic regulation of complement activity. Submitted 1995Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • J. L. Platt
  • J. S. Logan

There are no affiliations available

Personalised recommendations